Registration - In-house Organization

Innovative Medicines Canada / Médicaments novateurs Canada / Bettina Hamelin, President and CEO

Registration Information

In-house Organization name: Innovative Medicines Canada / Médicaments novateurs Canada
Previous in-house organization names
Responsible Officer Name: Bettina Hamelin, President and CEO
Responsible Officer Change History
Initial registration start date: 2004-08-19
Registration status: Active
Registration Number: 957857-371

Associated Communications

Total Number of Communication Reports: 1025

Monthly communication reports in the last 6 months: 46

Version 128 of 130 (2025-10-21 to 2025-11-03)

Registration versions:

Version 128 of 130 (2025-10-21 to 2025-11-03)

Lobbying Information

Subject Matter Details

Details Regarding the Identified Subject Matter
Subject matters	Details	Categories
Environment, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	Activities related to the Convention on Biological Diversity (CBD) including Digital Sequence Information (DSI) and an Access and Benefit Sharing (ABS) framework.	Policies or Program
Federal-Provincial Relations, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance	Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry	Legislative Proposal, Bill or Resolution
Foreign Affairs, Health, Infrastructure, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance	Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry	Policies or Program
Foreign Affairs, Health, Intellectual Property, International Trade, Research and Development, Science and Technology	Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products	Policies or Program
Environment, Health, Intellectual Property, Research and Development, Science and Technology	Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies	Legislative Proposal, Bill or Resolution, Regulation
Health, Research and Development, Science and Technology, Taxation and Finance	Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships	Policies or Program
Health, Intellectual Property, Research and Development, Science and Technology	Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework	Policies or Program
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance	Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)	Policies or Program
Health, Intellectual Property, International Trade, Research and Development, Science and Technology	Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products	Regulation
Agriculture, Consumer Issues, Foreign Affairs, Health, International Relations, International Trade, Taxation and Finance	Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals	Legislative Proposal, Bill or Resolution, Regulation
Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance	Free trade agreements as they relate to the biopharmaceutical industry	Policies or Program
Agriculture, Consumer Issues, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance	Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry	Regulation
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	Income Tax Act as it relates to biopharmaceutical products	Legislative Proposal, Bill or Resolution
Health, Industry, Intellectual Property, Research and Development, Science and Technology, Small Business, Taxation and Finance	National Strategy for Drugs for Rare Diseases	Regulation, Policies or Program
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance	Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products	Legislative Proposal, Bill or Resolution
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance	Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products	Regulation
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance	Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive	Regulation
Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance	Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products	Regulation
Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Health, Research and Development, Science and Technology	Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)	Policies or Program
Economic Development, Federal-Provincial Relations, Health, Intellectual Property, Research and Development, Science and Technology	Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes	Policies or Program
Federal-Provincial Relations, Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, National Security/Security, Research and Development, Science and Technology	Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations	Policies or Program
Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	Proposed pharmacare legislation related to any future national pharmacare program	Legislative Proposal, Bill or Resolution
Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance	Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits	Policies or Program
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations	Policies or Program
Agriculture, Government Procurement, Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	World Health Organization (WHO) issues concerning the biopharmaceutical industry	Policies or Program
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry	Policies or Program
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance	World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"	Policies or Program

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Agriculture and Agri-Food Canada (AAFC)
Canada Revenue Agency (CRA)
Canadian Institutes of Health Research (CIHR)
Canadian International Trade Tribunal (CITT)
Competition Tribunal (CT)
Employment and Social Development Canada (ESDC)
Environment and Climate Change Canada (ECCC)
Finance Canada (FIN)
Fisheries and Oceans Canada (DFO)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Justice Canada (JC)
National Research Council (NRC)
Natural Resources Canada (NRCan)
Natural Sciences and Engineering Research Council (NSERC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Services and Procurement Canada (PSPC)
Senate of Canada
Statistics Canada (StatCan)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Organization Details

Description of the organization's activities

Innovative Medicines Canada represents Canada’s innovative pharmaceutical industry. We help our members discover, develop, and deliver innovative medicines and vaccines. Our member companies which range from early-stage startups are revolutionizing healthcare through the discovery and development of new medicines and vaccines. Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and stakeholders to advance the field and enhance the wellbeing of Canadians. We are committed to being valued partners in Canada’s healthcare system. We aim to achieve these goals by forming effective alliances and supporting policies, improving Canada’s regulatory environment, widen access to innovative medicines and protect intellectual property.

Responsible officer name and position during the period of this registration

Bettina Hamelin, President and CEO

Organization's membership or classes of membership

Innovative Medicines Canada is comprised of member companies, which range from early-stage startups to established organizations, are revolutionizing healthcare through the discovery and development of new medicines and vaccines. The categories of memberships are (a) Full membership, which is open to innovative pharmaceutical companies that research, develop, manufacture and/or distribute pharmaceutical prescription preparations under their own labels in Canada, and (b) Life Sciences Associate membership, which is open to organizations who do not qualify as Full Members, who support the purposes of the association.

Government funding

No government funding was received during the last completed financial year.

In-house Organization Contact Information

Address:
99 Bank Street
Suite 310
Ottawa, ON K1P 6B9
Canada

Telephone number: 343-999-2112

Lobbyists Details

Employees who lobby for the organization

Charles Brown, Director, Government Affairs, West | Public offices held
Jennifer Buckley, Director, Policy | No public offices held
Michael Dietrich, Vice President, Market Access Policy | Public offices held
Jacqueline Dobson, Director, Government Affairs, Ontario | No public offices held
Joe Farago, Executive Director, Market Access | No public offices held
Bettina Hamelin, President and CEO | Public offices held
Greg Hein, Vice President, Strategy, Systems Transformation & Research | No public offices held
Olivier Jérôme, Director, Government Relations, Quebec & Strategic Alliances | No public offices held
Kristian LeBlanc, Senior Director, Atlantic, Government Relations | No public offices held
Brendan Lounsbery, General Counsel & Vice President, Legal, Compliance & Regulatory | No public offices held
Ashley McVey, Executive Director, Federal Government Relations | Public offices held
Sophie Normand, Director, Federal Government Relations | Public offices held
Hugh Scott, Executive Director, Strategic Alliances | Public offices held
Agata Stankiewicz, Senior Director, Government Relations, Ontario | Public offices held

Innovative Medicines Canada/Médicaments novateurs Canada

The following names have been used on or after July 2, 2008

Name	From	To
Innovative Medicines Canada/Médicaments novateurs Canada	2016-01-04	current
Canada's Research-Based Pharmaceutical Companies	2008-08-08	2016-01-04

The following names have been used before July 2, 2008

Canada's Research-Based Pharmaceutical Companies
Rx&D, Canada's Research Based Pharmaceutical Companies
RX&D
CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)

Innovative Medicines Canada / Médicaments novateurs Canada

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Bettina Hamelin	2024-04-08	Current
David Renwick	2023-11-17	2024-04-08
Pamela Fralick	2016-12-01	2023-11-17
Elaine Campbell	2016-06-13	2016-12-01
RUSSELL WILLIAMS	2004-08-19	2016-06-13

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Jr. Research Analyst Industry Canada, Industrial Analysis	2004 to 2004	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Vice President, Research Partnerships Council of Canada, Natural Sciences and Engineering Research Council of Canada	August 2015 to July 2017	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Trade Commissioner Global Affairs Canada, Toronto Office	September 2018 to November 2018	Not a designated office
Policy Analyst Public Health Agency of Canada, Office of International Affairs for the Health Portfolio	August 2016 to August 2018	Not a designated office
Policy Analyst Public Health Agency of Canada, Social Determinants and Science Integration Directorate	August 2012 to August 2016	Not a designated office
Epidemiologist Public Health Agency of Canada, Centre for Chronic Disease Prevention	August 2010 to August 2012	Not a designated office
Policy Officer Public Health Agency of Canada, Strategic Policy Branch	June 2009 to August 2010	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Senior Advisor, Program Delivery Health Canada, Office of Nutrition Policy and Promotion	August 2020 to November 2020	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Social Media Coordinator Senate of Canada, Communications Directorate	November 2020 to April 2021	Not a designated office
Social Media and Special Projects Coordinator Parliament of Canada, Office of the Speaker of the House of Commons	November 2018 to August 2019	Not a designated office
Director of Events (acting) Parliament of Canada, Office of the Speaker of the House of Commons	September 2018 to November 2018	Not a designated office
Administrative Assistant Parliament of Canada, Office of the Speaker of the House of Commons	March 2017 to September 2018	Not a designated office
Summer Student Parliament of Canada, Office of the Speaker of the House of Commons	April 2016 to March 2017	Not a designated office
Page Parliament of Canada, House of Commons	August 2013 to August 2014	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Labour Market Economic Analyst Employment and Immigration Canada, Economic Services	September 1989 to September 1992	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Legislative Assistant to Albina Guarnieri, M.P. - Parliamentary Secretary to the Minister of Canadian Heritage Canadian Heritage, Parliament Hill Office	1994 to March 1998	Not a designated office

Date Modified:: 2026-01-27

Search and menus

Language selection

Registration - In-house Organization

Innovative Medicines Canada / Médicaments novateurs Canada / Bettina Hamelin, President and CEO

Registration Information

Associated Communications

Version 128 of 130 (2025-10-21 to 2025-11-03)

Version 128 of 130 (2025-10-21 to 2025-11-03)

Subject Matter Details

Communication Techniques

Government Institutions

Description of the organization's activities

Responsible officer name and position during the period of this registration

Organization's membership or classes of membership

Government funding

In-house Organization Contact Information

Employees who lobby for the organization